IMMUNE-ONC THERAPEUTICS
Immune-Onc Therapeutics is a newly established bio-pharmaceutical company that focuses on developing innovative therapeutic antibodies for cancer treatment. The company applies the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients.
IMMUNE-ONC THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical Therapeutics
Founded:
2016-01-01
Address:
Palo Alto, California, United States
Country:
United States
Website Url:
http://www.immune-onc.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
115.14 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Content Delivery Network Organization Schema Cloudflare JS CDN JS GoDaddy DNS Typekit
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Intellia Therapeutics
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Employees Featured
Founder
Investors List
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Series B - Immune-Onc Therapeutics
Oceanpine Capital
Oceanpine Capital investment in Series B - Immune-Onc Therapeutics
Northern Light Venture Capital
Northern Light Venture Capital investment in Series B - Immune-Onc Therapeutics
Vivo Capital
Vivo Capital investment in Series B - Immune-Onc Therapeutics
Octagon Capital Advisors
Octagon Capital Advisors investment in Series B - Immune-Onc Therapeutics
Leukemia & Lymphoma Society
Leukemia & Lymphoma Society investment in Series B - Immune-Onc Therapeutics
National Cancer Institute
National Cancer Institute investment in Grant - Immune-Onc Therapeutics
Vivo Capital
Vivo Capital investment in Series B - Immune-Onc Therapeutics
StartX (Stanford-StartX Fund)
StartX (Stanford-StartX Fund) investment in Series B - Immune-Onc Therapeutics
Northern Light Venture Capital
Northern Light Venture Capital investment in Series B - Immune-Onc Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-14 | Immune-Onc Therapeutics Announces Appointment of Christopher Whitmore as Chief Financial Officer and Provides Clinical Progress Update |
Official Site Inspections
http://www.immune-onc.com Semrush global rank: 4.49 M Semrush visits lastest month: 2.39 K
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Immune-Onc Therapeutics"
Immune-Onc Therapeutics - Crunchbase Company …
Immune-Onc Therapeutics is a newly established biopharmaceutical company that develops therapeutic antibodies for cancer treatment.See details»
Immune-Onc Therapeutics - Org Chart, Teams, Culture & Jobs
View Immune-Onc Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Team — Immune-Onc Therapeutics
Chief Medical Advisor Dr. Klencke is an Independent Board Member of Immune-Onc Therapeutics, Inc. and a world-class drug developer and research & development expert, …See details»
Immune-Onc Therapeutics | Leukemia and Lymphoma …
Apr 20, 2021 Immune-Onc is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients.See details»
Company Profile for Immune-Onc Therapeutics, Inc.
Nov 21, 2019 Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biolSee details»
Immune-Onc Therapeutics, Inc. - Drug pipelines, Patents, Clinical ...
Immune-Onc Therapeutics Inc. (“Immune-Onc”) is a private, clinical-stage biopharmaceutical company developing novel therapies in immunology and oncology by targeting myeloid cell …See details»
Immune-Onc Therapeutics | Leukemia and Lymphoma Society
Immune-Onc is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The …See details»
Immune-Onc Therapeutics Announces $73 Million Financing to …
PALO ALTO, CA, March 30, 2021 / Business Wire / -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics …See details»
Immune-Onc Adds $25 Million to B Round for Novel Myeloid …
Immune-Onc is a Palo Alto, CA-Hangzhou company that is developing novel checkpoint inhibitors for cancer. In 2022, BayHelix, the global organization of China life science business leaders, …See details»
Immune-Onc Therapeutics Announces Clinical Trial Collaboration …
Feb 20, 2024 Immune-Onc Therapeutics Inc. ("Immune-Onc") is a private, clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies in …See details»
Immune-Onc Therapeutics Announces $73 Million in Series B1 and …
Mar 30, 2021 Immune-Onc’s lead program IO-202, a first-in-class antibody targeting LILRB4 (also known as ILT3), is being developed to treat blood cancers, including acute myeloid …See details»
IC-ONC: Building Local Communities in a Global Network
IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education. Educational …See details»
Immune-Onc Therapeutics - Funding, Financials, Valuation
Immune-Onc Therapeutics is a newly established biopharmaceutical company that develops therapeutic antibodies for cancer treatment.See details»
Immune-Onc Therapeutics, Inc. (Immune-Onc Therapeutics, Inc.)
Immune-Onc Therapeutics Inc. (“Immune-Onc”) is a private, clinical-stage biopharmaceutical company developing novel therapies in immunology and oncology by targeting myeloid cell …See details»
Multi-omics in immunotherapy research for HNSCC: present
2 days ago With advancements in omics technologies and the growing prevalence of bioinformatics research, the immune microenvironment of HNSCC has become increasingly …See details»
Immune-Onc Therapeutics - Contacts, Employees, Board
Immune-Onc Therapeutics is a newly established biopharmaceutical company that develops therapeutic antibodies for cancer treatment.See details»
Immune-Onc Therapeutics Announces Close of Series B Extension …
PALO ALTO, CA, January 5, 2023 - Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting …See details»
Cancer vaccines: current status and future directions
Feb 17, 2025 Cancer continues to be a major global health burden, with high morbidity and mortality. Building on the success of immune checkpoint inhibitors and adoptive cellular …See details»
Karen Knudsen, MBA PhD, Appointed Chief Executive Officer of …
18 hours ago About the Parker Institute for Cancer Immunotherapy The Parker Institute for Cancer Immunotherapy (PICI) is a 501c3 nonprofit organization driving the next generation of …See details»
What is cancer immunotherapy? - cancerblog.mayoclinic.org
Feb 26, 2025 The body has a built-in defense: the immune system, which consists of white blood cells, lymph system tissues and organs that work together to identify and destroy infections …See details»